VIRIDIAN THERAPEUTICS INC (VRDN) Stock Analyst Ratings
NASDAQ:VRDN • US92790C1045
29.38 USD
-0.11 (-0.37%)
At close: Feb 27, 2026
29.38 USD
0 (0%)
After Hours: 2/27/2026, 8:00:02 PM
ChartMill assigns a Buy % Consensus number of 85% to VRDN. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 41.04. This target is 39.69% above the current price.
- VRDN was analyzed by 25 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about VRDN.
- In the previous month the buy percentage consensus was at a similar level.
- VRDN was analyzed by 25 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-27 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-04 | Needham | Reiterate | Buy -> Buy |
| 2026-02-03 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-08 | Truist Securities | Maintains | Buy -> Buy |
| 2026-01-07 | UBS | Initiate | Buy |
| 2025-12-23 | Needham | Maintains | Buy -> Buy |
| 2025-12-10 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-12-03 | William Blair | Initiate | Outperform |
| 2025-11-24 | Truist Securities | Initiate | Buy |
| 2025-11-06 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-04 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-21 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-08-07 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-08-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-07 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-07 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-08-06 | Needham | Maintains | Buy -> Buy |
| 2025-05-20 | Needham | Reiterate | Buy -> Buy |
| 2025-05-07 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-05-07 | Needham | Maintains | Buy -> Buy |
| 2025-05-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-07 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-07 | Needham | Reiterate | Buy -> Buy |
| 2024-12-19 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-12-17 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-12-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-05 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-25 | TD Cowen | Initiate | Buy |
VIRIDIAN THERAPEUTICS INC / VRDN FAQ
What is the price target for VRDN stock?
25 analysts have analysed VRDN and the average price target is 41.04 USD. This implies a price increase of 39.69% is expected in the next year compared to the current price of 29.38.
What is the consensus rating for VIRIDIAN THERAPEUTICS INC (VRDN) stock?
The consensus rating for VIRIDIAN THERAPEUTICS INC (VRDN) is 84.8 / 100 . This indicates that analysts generally have a positive outlook on the stock.